Pazopanib therapy for children, adolescents, and young adults with relapsed and refractory sarcomas
In a small cohort of children and adolescent and young adult patients with heavily pretreated relapsed or refractory sarcoma, pazopanib may be a feasible option. Further research on optimal therapeutic timing and the target population for pazopanib's indication is required.
Authors
- Toshifumi Ozaki (ORCID: https://orcid.org/0000-0003-1732-9307)
- Go Makimoto (ORCID: https://orcid.org/0000-0002-0638-8435)
- Yasuhisa Tatebe (ORCID: https://orcid.org/0000-0001-6711-2136)
- Tomohiro Fujiwara (ORCID: https://orcid.org/0000-0003-4257-9180)
- Hisashi Ishida (ORCID: https://orcid.org/0000-0002-3391-8403)
- Motoharu Ochi (ORCID: https://orcid.org/0000-0002-6484-8137)
- Kaori Fujiwara (ORCID: https://orcid.org/0000-0001-7414-5761)
- Kosuke Tamefusa (ORCID: https://orcid.org/0000-0002-1675-7038)
- Kana Washio (ORCID: https://orcid.org/0000-0001-6126-0189)
- T. Shiwaku (ORCID: https://orcid.org/0009-0001-0900-1953)
- Hirokazu Tsukahara (ORCID: https://orcid.org/0000-0002-6432-9038)
- Masahiro Tabata
Institutions
- Okayama University Hospital (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-11-16
- DOI
- https://doi.org/10.1093/jjco/hyaf191
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00